New drug aims to tame rare bleeding disorder

NCT ID NCT06659640

Ongoing Disease control Sponsor: Alnylam Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 4 times

Summary

This study tests a new medicine called ALN-6400 for people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes abnormal blood vessels and frequent nosebleeds. First, healthy volunteers will receive a single dose to check safety. Then, HHT patients will receive multiple doses to see if it reduces bleeding. The goal is to control the disease, not cure it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Epistaxis hereditary hemorrhagic telangiectasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEREDITARY HEMORRHAGIC TELANGIECTASIA

Contacts and locations

Locations

Clinical Trial Site

Birmingham, Alabama, 35249, United States
Clinical Trial Site

Cypress, California, 90630, United States
Clinical Trial Site

Gainesville, Florida, 32608, United States
Clinical Trial Site

Indianapolis, Indiana, 46260, United States
Clinical Trial Site

Boston, Massachusetts, 02114, United States
Clinical Trial Site

Rochester, Minnesota, 55905, United States
Clinical Trial Site

St Louis, Missouri, 63110, United States
Clinical Trial Site

Chapel Hill, North Carolina, 27514, United States
Clinical Trial Site

Camperdown, 2050, Australia
Clinical Trial Site

Parkville, 3050, Australia
Clinical Trial Site

Mount Royal, H3P 3P1, Canada
Clinical Trial Site

Toronto, M5B 1W8, Canada
Clinical Trial Site

Bordeaux, 33000, France
Clinical Trial Site

Bron, 69500, France
Clinical Trial Site

Homburg, 66421, Germany
Clinical Trial Site

L'Hospitalet de Llobregat, 8907, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.